Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Haematologica. 2024 Sep 1;109(9):3042-3047. doi: 10.3324/haematol.2023.284950.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Antibodies, Bispecific* / administration & dosage
  • Antibodies, Bispecific* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Child
  • Child, Preschool
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Inotuzumab Ozogamicin*
  • Male
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / pathology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / therapy
  • Recurrence
  • Rituximab* / administration & dosage
  • Rituximab* / therapeutic use
  • Treatment Outcome

Substances

  • blinatumomab
  • Inotuzumab Ozogamicin
  • Antibodies, Bispecific
  • Rituximab